Robeco Institutional Asset Management B.V. Acquires 116,612 Shares of Becton, Dickinson and Company $BDX

Robeco Institutional Asset Management B.V. lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 271.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 159,520 shares of the medical instruments supplier’s stock after purchasing an additional 116,612 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Becton, Dickinson and Company were worth $28,554,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Wagner Wealth Management Corp acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $473,000. Revisor Wealth Management LLC lifted its position in shares of Becton, Dickinson and Company by 4.6% during the 3rd quarter. Revisor Wealth Management LLC now owns 13,066 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 574 shares during the period. Norway Savings Bank lifted its position in shares of Becton, Dickinson and Company by 9.7% during the 3rd quarter. Norway Savings Bank now owns 8,040 shares of the medical instruments supplier’s stock valued at $1,439,000 after acquiring an additional 711 shares during the period. Net Worth Advisory Group grew its holdings in shares of Becton, Dickinson and Company by 46.4% during the 3rd quarter. Net Worth Advisory Group now owns 5,365 shares of the medical instruments supplier’s stock worth $955,000 after purchasing an additional 1,701 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Becton, Dickinson and Company by 18.9% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,413 shares of the medical instruments supplier’s stock worth $7,771,000 after purchasing an additional 6,887 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 6,906 shares of company stock worth $1,265,855. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7%

Shares of Becton, Dickinson and Company stock opened at $198.96 on Friday. The firm’s 50 day moving average is $185.41 and its 200 day moving average is $165.10. The firm has a market capitalization of $54.82 billion, a PE ratio of 59.93, a price-to-earnings-growth ratio of 13.51 and a beta of 0.21. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $200.47. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $3.68 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BDX. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Bank of America increased their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Finally, TD Cowen boosted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.